Colorectal cancers (CRCs) with oncogenic mutations in RAS and BRAF are associated with anti-EGFR therapy resistance. Consequently, all RAS mutant CRC patients are being excluded from this therapy. However, heterogeneity in drug response has been reported between RAS mutant CRC patients. It is poorly understood to what extent such differences are derived from different genetic backgrounds or intrinsic differences between the various RAS pathway mutations. Therefore, using CRISPR technology we generated an isogenic panel of patientderived CRC organoids with various RAS pathway mutations (i.e. KRAS G12D , BRAF V600E , KRAS G13D and NRAS G12D ). All RAS pathway mutants promote ERK activation and tumor growth. However, KRAS G12D and BRAF V600E mutations in particular conferred robust resistance to anti-EGFR therapy, both in vitro and in vivo. Moreover, untreated KRAS G13D mutants showed fastest growth in mice but remained sensitive to anti-EGFR therapy. Together, introducing mutationspecific oncogene signaling in CRC organoids resembles clinical phenotypes and improves understanding of genotype-phenotype correlations.